Comparing Chemoprevention Drugs for School-based Malaria Control

Status Completed

Clinical Trial Summary

This is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent preventive treatment with dihydroartemisinin-piperaquine (IPT-DP). Arm 2: Intermittent preventive treatment with sulfadoxine-pyrimethamine (SP) plus chloroquine (CQ) (IPT-SPCQ). Arm 3: Control - students will receive standard of care (no preventive treatment). Outcomes include P. falciparum infection and parasite density, anemia, cognitive function and educational testing, as well as infection prevalence in young children sleeping student's households to assess the impact on transmission.

Clinical Trial Description

Students attending a single primary school in Machinga District, Malawi who were enrolled in NCT05244954 were offered enrollment in this follow-on study. The intervention will be conducted every 6-weeks during the two school terms which coincide with peak malaria transmission. Students in the IPT-DP arm will be treated with with dihydroartemisinin-piperaquine (DP) (females less than 10 years old and all males) or chloroquine (females 10 years old or older. Students in the IPT-SPCQ arm will be treated with sulfadoxine-pyrimethamine plus chloroquine (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05980156
Study type	Interventional
Source	University of Maryland, Baltimore
Contact
Status	Completed
Phase	Phase 4
Start date	February 13, 2023
Completion date	July 28, 2023

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04130282` - VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine	Phase 1
Completed	`NCT04049916` - Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission	Phase 2/Phase 3
Active, not recruiting	`NCT03814616` - Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections	Phase 2
Active, not recruiting	`NCT04079621` - Short Course Radical Cure of P. Vivax Malaria in Nepal	Phase 4
Completed	`NCT05135273` - Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali	Phase 1
Not yet recruiting	`NCT06083688` - Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi	Phase 4
Recruiting	`NCT03511443` - Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections	N/A
Completed	`NCT05550909` - Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali	Phase 2
Recruiting	`NCT05306067` - Plasmodium Falciparum Genomic Intelligence in Mozambique
Completed	`NCT05081089` - Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali	Phase 2
Recruiting	`NCT05150808` - Vectron T500 (Broflanilide 50WP) for IRS in Tanzania Tanzania	Phase 3
Recruiting	`NCT05757167` - Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics	Phase 4
Completed	`NCT01992900` - A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria	Phase 2
Completed	`NCT04565184` - Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde	Phase 4
Completed	`NCT03896724` - Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso	Phase 1/Phase 2
Completed	`NCT03454048` - Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2	N/A
Recruiting	`NCT04844905` - Adjunctive Ivermectin Mass Drug Administration for Malaria Control	Phase 3
Completed	`NCT03138096` - Safety and Protective Efficacy of Pb(PfCS@UIS4)	Phase 1/Phase 2
Recruiting	`NCT04271306` - Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.	Phase 1
Recruiting	`NCT05058885` - Plasmodium Vivax Among Duffy Negative Population in Cameroon.